STOCK TITAN

111, Inc. Announces Second Quarter 2023 Unaudited Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags
Rhea-AI Summary
111, Inc. reports Q2 2023 financial results with net revenues of RMB3.5 billion, representing a 14.5% YoY increase. Gross segment profit increased by 8.3% YoY. Total operating expenses decreased to 7.2% of net revenues. Loss from operations decreased to RMB41.4 million, down from RMB79.8 million in the same quarter last year. Non-GAAP loss from operations decreased to RMB17.2 million. Net loss decreased to RMB45.4 million, down from RMB84.8 million in the same quarter last year. Cash and cash equivalents as of June 30, 2023, were RMB735.8 million.
Positive
  • Net revenues increased by 14.5% YoY
  • Total operating expenses decreased to 7.2% of net revenues
  • Loss from operations decreased to RMB41.4 million
Negative
  • None.

SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the second quarter ended June 30, 2023.

Second Quarter 2023 Highlights

  • Net revenues were RMB3.5 billion (US$479.6 million), representing an increase of 14.5% year-over-year.
  • Gross segment profit(1) increased by 8.3% year-over-year, with B2B segment profit increasing by 11.6% year-over-year.
  • Total operating expenses were RMB249.3million (US$34.4million), compared to RMB271.7 million in the same quarter of last year. As a percentage of net revenues, total operating expenses decreased to 7.2% from 8.9% in the same quarter of last year, which reflected continuous improvement in our operation efficiency.
  • Loss from operations was RMB41.4 million (US$5.7 million), compared to RMB79.8 million in the same quarter of last year. As a percentage of net revenues, loss from operations decreased to 1.2% from 2.6% in the same quarter of last year.
  • Non-GAAP loss from operations(2) was RMB17.2 million (US$2.4 million), compared to RMB52.8 million in the same quarter of last year. As a percentage of net revenues, non-GAAP loss from operations decreased to 0.5% from 1.7% in the same quarter of last year.

(1) Gross segment profit represents net revenues less cost of goods sold.

(2) Non-GAAP loss from operations represents loss from operations excluding share-based compensation expenses.

Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, commented, "We're delighted to announce yet another robust quarter in terms of top-line expansion with narrowed losses both on a GAAP and a Non-GAAP operational basis. Our net revenue saw a rise of 14.5% year-over-year, reaching RMB3.5 billion. This represents the 20th consecutive quarter of year-over-year progression for 111 since our NASDAQ IPO. Additionally, our gross segment profit for this quarter rose by 8.3% compared to the same period last year. Consequently, our operational loss stood at RMB41.4 million (US$5.7 million), down from RMB79.8 million during the same quarter the previous year. When viewed as a percentage of net revenues, the operational loss reduced to 1.2%, compared to 2.6% in the corresponding quarter of the prior year. Meanwhile, Non-GAAP operational loss reduced to RMB17.2 million, dropping to 0.5% of net revenues from the previous 1.7% during the same quarter of the preceding year."

Mr. Liu added, "Furthermore, we've made strides in improving our operational efficiency, with total operating expenses as a percentage of net revenues falling to 7.2% this quarter, down from 8.9% in the corresponding quarter of the previous year. We anticipate maintaining this positive trajectory as we expand. Concurrently, our dedication remains steadfast in providing top-tier services to our customers and patients."

"Our recent achievements are a direct result of our unwavering strategic focus, particularly on digitization. In June, we forged a strategic alliance with Tencent to amplify the reach of online pharmaceutical services. By July, 111 secured a spot on the Shanghai Data Exchange, propelling the digital transformation of the pharmaceutical landscape. That same month, we unveiled a pivotal digital supply chain product, bolstering the momentum of supply-side digitization. This quarter, in acknowledgment of 111's digital prowess, the Ministry of Commerce distinguished us as an E-commerce Demonstration Enterprise, placing us among the top 132 nationwide. Capitalizing on our reinforced digital capabilities and robust relationships with over 500 pharmaceutical allies, as well as optimizing operations for 435,000 retail pharmacies, we remain committed to fine-tuning our strategies, and will keep on capitalizing on innovative tools like "Telescope" and tapping into the latest tech advancements, ensuring sustained growth and efficiency.

"We are confident that our initiatives aimed at margin expansion, cost optimization, and organizational alignment have yielded tangible outcomes. Our focus remains on refining our product selection in line with customer preferences, driving down costs through direct sourcing, and enhancing our market edge with smart pricing strategies. Our commitment to supply chain efficiency and relentless digitization bolsters process enhancement and sparks innovation. With our robust technological prowess, we're poised to scale further, ensure profitability, and consistently amplify value for our shareholders."

Second Quarter 2023 Financial Results

Net revenues were RMB3.5 billion (US$479.6 million), representing an increase of 14.5% from RMB3.0 billion in the same quarter of last year.

(In thousands RMB)

For the three months ended June 30,


2022


2023


YoY

B2B Net Revenue






Product

2,919,468


3,367,732


15.4 %

Service

15,155


20,974


38.4 %







Sub-Total

2,934,623


3,388,706


15.5 %







Cost of Products Sold(3)

2,765,701


3,200,156


15.7 %







Segment Profit

168,922


188,550


11.6 %

Segment Profit %

5.8 %


5.6 %





(In thousands RMB)

For the three months ended June 30,


2022


2023


YoY

B2C Net Revenue






Product

95,879


83,251


-13.2 %

Service

6,643


5,540


-16.6 %







Sub-Total

102,522


88,791


-13.4 %







Cost of Products Sold

79,477


69,454


-12.6 %







Segment Profit

23,045


19,337


-16.1 %

Segment Profit %

22.5 %


21.8 %



(3) For segment reporting purposes, purchase rebates are allocated to the B2B segment and B2C segments primarily based on the amount of cost of products sold for each segment. Cost of products sold does not include other direct costs related to cost of product sales such as shipping and handling expense, payroll and benefits of logistic staff, logistic centers rental expenses and depreciation expenses, which are recorded in the fulfillment expenses. Cost of service revenue is recorded in the operating expense.

Operating costs and expenses were RMB3.5 billion (US$485.3 million), representing an increase of 12.9% from RMB3.1 billion in the same quarter of last year.

  • Cost of products sold was RMB3.3 billion (US$450.9 million), representing an increase of 14.9% from RMB2.8 billion in the same quarter of last year. The increase was primarily due to the revenue growth in B2B business, which increased by 15.4% from the same quarter last year.

  • Fulfillment expenses were RMB95.0 million (US$13.1 million), representing an increase of 8.0% from RMB87.9 million in the same quarter of last year. Fulfillment expenses accounted for 2.7% of net revenues this quarter as compared to 2.9% in the same quarter of last year. 

  • Selling and marketing expenses were RMB90.1 million (US$12.4 million), representing a decrease of 10.9% from RMB101.2 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB4.4 million for the quarter and RMB8.4 million for the same quarter last year, respectively, selling and marketing expenses as a percentage of net revenues, accounted for 2.5% in the quarter as compared to 3.1% in the same quarter of last year.

  • General and administrative expenses were RMB39.1 million (US$5.4 million), representing an increase of 1.5% from RMB38.5 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB15.7 million for the quarter and RMB17.0 million for the same quarter last year, respectively, general and administrative expenses as a percentage of net revenues, accounted for 0.7% in the quarter, which  was same as last year.

  • Technology expenses were RMB24.5 million (US$3.4 million), compared with RMB33.7 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB4.2 million for the quarter and RMB1.6 million for the same quarter last year, respectively, technology expenses as a percentage of net revenues, accounted for 0.6% in the quarter as compared to 1.1 % in the same quarter of last year.

Loss from operations was RMB41.4 million (US$5.7 million), compared to RMB79.8 million in the same quarter of last year. As a percentage of net revenues, loss from operations decreased to 1.2 % in the quarter from 2.6% in the same quarter of last year.

Non-GAAP loss from operations was RMB17.2 million (US$2.4 million), compared to RMB52.8 million in the same quarter of last year. As a percentage of net revenues, non-GAAP loss from operations decreased to 0.5% in the quarter from 1.7% in the same quarter of last year.

Net loss was RMB45.4 million (US$6.3 million), compared to RMB84.8 million in the same quarter of last year. As a percentage of net revenues, net loss decreased to 1.3% in the quarter from 2.8% in same quarter of last year.

Non-GAAP net loss(4) was RMB21.2 million (US$2.9 million), compared to RMB57.8 million in the same quarter of last year. As a percentage of net revenues, non-GAAP net loss decreased to 0.6% in the quarter from 1.9% in same quarter of last year

Net loss attributable to ordinary shareholders was RMB57.2 million (US$7.9 million), compared to RMB95.3 million in the same quarter of last year. As a percentage of net revenues, net loss attributable to ordinary shareholders decreased to 1.6% in the quarter from 3.1% in same quarter of last year.

Non-GAAP net loss attributable to ordinary shareholders(5) was RMB33.0 million (US$4.6 million), compared to RMB68.3 million in the same quarter of last year. As a percentage of net revenues, non-GAAP net loss attributable to ordinary shareholders decreased to 0.9% in the quarter from 2.2% in same quarter of last year.

(4) Non-GAAP net loss represents net loss excluding share-based compensation expenses, net of tax. Considering the impact of accretion of redeemable non-controlling interest for the second quarter 2023, non-GAAP net loss is used as a more meaningful measurement of the operation performance of the Company.

(5) Non-GAAP net loss attributable to ordinary shareholders represents net loss attributable to ordinary shareholders excluding share-based compensation expenses, net of tax.

As of June 30, 2023, the Company had cash and cash equivalents, restricted cash and short-term investments of RMB735.8 million (US$101.5 million), compared to RMB922.7 million as of December 31, 2022.

Conference Call

111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 24, 2023 (7:30 PM Beijing Time on the same day).

Details for the conference call are as follows:

Event Title: 111, Inc. Second Quarter 2023 Unaudited Financial Results

Registration Link: https://s1.c-conf.com/diamondpass/10032701-ygfhis.html 

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.

Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.

A telephone replay of the call will be available after the conclusion of the conference call until August 31, 2023 on:

China: 4001 209 216
Hong Kong: 800 930 639
United States: +1 855 883 1031
International: +61 7 3107 6325
Conference ID: 10032701

A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/iw7ck9oc.

Use of Non-GAAP Financial Measures

In evaluating the business, the Company considers and uses non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS, as supplemental measures to review and assess its operating performance. The Company defines non-GAAP loss from operations as loss from operations excluding share-based compensation expenses. The Company defines non-GAAP net loss as net loss excluding share-based compensation expenses, net of tax. The Company defines non-GAAP net loss attributable to ordinary shareholders as net loss attributable to ordinary shareholders excluding share-based compensation expenses, net of tax. The Company defines non-GAAP loss per ADS as net loss attributable to ordinary shareholders per ADS excluding share-based compensation expenses, net of tax per ADS. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP.

The Company believes that non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that it includes in loss from operations and net loss. Share-based compensation expenses is a non-cash expense that varies from period to period. As a result, management excludes the items from its internal operating forecasts and models. Management believes that the adjustments for share-based compensation expenses provide investors with a reasonable basis to measure the company's core operating performance, in a more meaningful comparison with the performance of other companies. The Company believes that non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by the management in their financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, or non-GAAP loss per ADS is that it does not reflect all items of income and expense that affect the Company's operations. Further, the non-GAAP financial measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.

The Company compensates for these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP measures, all of which should be considered when evaluating the Company's performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure.

Reconciliation of the non-GAAP financial measures to the most comparable U.S. GAAP measures is included at the end of this press release.

Exchange Rate Information Statement 

This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.2513 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of June 30, 2023.

Forward-Looking Statements

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

About 111, Inc.

111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.

For more information on 111, please visit: http://ir.111.com.cn/.

For more information, please contact:

111, Inc.
Investor Relations
Email: ir@111.com.cn 

111, Inc.
Media Relations
Email: press@111.com.cn
Phone: +86-021-2053 6666 (China)

111, Inc.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except for share and per share data)



As of

As of


December 31, 2022

June 30, 2023


RMB



RMB


US$

ASSETS







Current Assets:







Cash and cash equivalents

673,669



576,414


79,491

Restricted cash

43,122



36,360


5,014

Short-term investments

205,861



123,049


16,969

Accounts receivable, net

488,875



452,003


62,334

Notes Receivable

43,332



63,934


8,817

Inventories

1,498,900



1,387,646


191,365

Prepayments and other current assets

282,066



192,692


26,574

Total current assets

3,235,825



2,832,098


390,564

Property and equipment, net

48,497



41,538


5,728

Intangible assets, net

3,267



2,666


368

Long-term investments

2,000



2,000


276

Other non-current assets

20,348



21,435


2,956

Operating lease right-of-use asset

163,877



150,418


20,744

Total Assets

3,473,814



3,050,155


420,636








LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS'
DEFICIT







Current Liabilities:







Short-term borrowings

178,990



309,698


42,709

Accounts payable

1,764,849



1,512,859


208,633

Accrued expense and other current liabilities

781,271



498,256


68,713

Total Current liabilities

2,725,110



2,320,813


320,055

Long-term operating lease liabilities

100,469



88,638


12,224

Total Liabilities

2,825,579



2,409,451


332,279








MEZZANINE EQUITY







Redeemable non-controlling interests

1,056,939



1,084,753


149,594








SHAREHOLDERS' DEFICIT







Ordinary shares Class A

31



32


5

Ordinary shares Class B

25



25


3

Treasury shares

(40,859)



(40,859)


(5,635)

Additional paid-in capital

2,977,174



3,028,583


417,661

Accumulated deficit

(3,426,556)



(3,515,582)


(484,821)

Accumulated other comprehensive income

75,586



81,715


11,269

Total shareholders' deficit

(414,599)



(446,086)


(61,518)

Non-controlling interest

5,895



2,037


281

Total Deficit

(408,704)



(444,049)


(61,237)

Total liabilities, mezzanine equity and deficit

3,473,814



3,050,155


420,636

 

 

 

111, Inc.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, except for share and per share data)



For the three months ended June 30,


For the six months ended June 30,


2022


2023


2022


2023


RMB


RMB


US$


RMB


RMB


US$

Net Revenues

3,037,145


3,477,497


479,568


6,019,736


7,174,258


989,376

Operating Costs and expenses:












 Cost of products sold

(2,845,178)


(3,269,610)


(450,900)


(5,635,234)


(6,730,158)


(928,131)

 Fulfillment expenses

(87,908)


(94,950)


(13,094)


(182,441)


(197,600)


(27,250)

 Selling and marketing expenses

(101,174)


(90,117)


(12,428)


(216,028)


(179,357)


(24,734)

 General and administrative expenses

(38,493)


(39,079)


(5,389)


(86,488)


(80,396)


(11,087)

 Technology expenses

(33,711)


(24,541)


(3,384)


(72,732)


(49,857)


(6,876)

 Other operating income, net

(10,434)


(605)


(83)


(8,718)


(27)


(4)

Total Operating costs and expenses

(3,116,898)


(3,518,902)


(485,278)


(6,201,641)


(7,237,395)


(998,082)

Loss from operations

(79,753)


(41,405)


(5,710)


(181,905)


(63,137)


(8,706)

 Interest income

1,421


2,206


304


3,464


4,155


573

 Interest expense

(3,185)


(4,820)


(665)


(6,369)


(9,092)


(1,254)

 Foreign exchange loss

(4,934)


(2,808)


(387)


(4,543)


(1,174)


(162)

 Other Income, net

1,687


1,450


200


3,600


4,514


623

Loss before income taxes

(84,764)


(45,377)


(6,258)


(185,753)


(64,734)


(8,926)

 Income tax expense

-


-


-


-


-


-

Net Loss

(84,764)


(45,377)


(6,258)


(185,753)


(64,734)


(8,926)

Net Loss attributable to non-controlling interest

3,489


2,122


293


7,966


3,522


486

Net Loss attributable to redeemable non-controlling interest

7,121


3,728


514


16,256


5,276


728

Adjustment attributable to redeemable non-controlling interest

(21,104)


(17,712)


(2,443)


(44,070)


(33,090)


(4,563)

Net Loss attributable to ordinary shareholders

(95,258)


(57,239)


(7,894)


(205,601)


(89,026)


(12,275)

Other comprehensive loss












 Unrealized gains of available-for-sale securities,

1,478


788


109


2,776


2,923


403

 Realized gains of available-for-sale debt securities

(1,128)


(815)


(112)


(2,463)


(2,717)


(375)

 Foreign currency translation adjustments

7,183


9,037


1,246


6,227


5,924


817

Comprehensive loss

(87,725)


(48,229)


(6,651)


(199,061)


(82,896)


(11,430)

Loss per ADS:












 Basic and diluted

(1.14)


(0.68)


(0.10)


(2.48)


(1.06)


(0.14)

Weighted average number of shares used in computation of loss per share












 Basic and diluted

166,595,078


168,102,392


168,102,392


166,463,376


167,718,135


167,718,135

 

 

 

111, Inc.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)



For the three months ended June 30,


For the six months ended June 30,


2022


2023


2022


2023


RMB


RMB


US$


RMB


RMB


US$













Net cash used in operating activities

(29,935)


(164,111)


(22,632)


(98,176)


(285,439)


(39,365)

Net cash (used in) provided by investing activities

(52,294)


139,938


19,298


(29,435)


86,750


11,964

Net cash provided by financing activities

6,394


15,281


2,107


41,672


93,778


12,933

Effect of exchange rate changes on cash and cash equivalents, and restricted cash

6,695


2,385


329


5,964


894


123

Net decrease in cash and cash equivalents, and restricted cash

(69,140)


(6,507)


(898)


(79,975)


(104,017)


(14,345)

Cash and cash equivalents, and restricted cash at the beginning of the period

749,837


619,281


85,403


760,672


716,791


98,850

Cash and cash equivalents, and restricted cash at the end of the period

680,697


612,774


84,505


680,697


612,774


84,505

 

 

 

111, Inc.

Unaudited Reconciliation of GAAP and Non-GAAP Results

(In thousands, except for share and per share data)



For the three months ended June 30,


For the six months ended June 30,


2022


2023


2022


2023


RMB


RMB


US$


RMB


RMB


US$













Loss from operations

(79,753)


(41,405)


(5,710)


(181,905)


(63,137)


(8,706)

Add: Share-based compensation expenses

26,997


24,208


3,338


56,754


48,416


6,677

Non-GAAP loss from operations

(52,756)


(17,197)


(2,372)


(125,151)


(14,721)


(2,029)













Net Loss

(84,764)


(45,377)


(6,258)


(185,753)


(64,734)


(8,926)

Add: Share-based compensation expenses, net of tax

26,997


24,208


3,338


56,754


48,416


6,677

Non-GAAP net Loss

(57,767)


(21,169)


(2,920)


(128,999)


(16,318)


(2,249)













Net Loss attributable to ordinary shareholders

(95,258)


(57,239)


(7,894)


(205,601)


(89,026)


(12,275)

Add: Share-based compensation expenses, net of tax

26,997


24,208


3,338


56,754


48,416


6,677

Non-GAAP net Loss attributable to ordinary shareholders

(68,261)


(33,031)


(4,556)


(148,847)


(40,610)


(5,598)













Loss per ADS(6): Basic and diluted

(1.14)


(0.68)


(0.10)


(2.48)


(1.06)


(0.14)

Add: Share-based compensation expenses per ADS(6), net of tax

0.32


0.30


0.04


0.68


0.58


0.08

Non-GAAP Loss per ADS(6)

(0.82)


(0.38)


(0.06)


(1.80)


(0.48)


(0.06)


(6) Every one ADSs represent two Class A ordinary shares.

 

 

Cision View original content:https://www.prnewswire.com/news-releases/111-inc-announces-second-quarter-2023-unaudited-financial-results-301908866.html

SOURCE 111, Inc.

111, Inc.

NASDAQ:YI

YI Rankings

YI Latest News

YI Stock Data

88.66M
68.54M
16.16%
27.08%
0.01%
Pharmacies and Drug Stores
Retail Trade
Link
United States of America
Shanghai